L-glutamine alters HSP levels and normalises energy status in patients with atrial fibrillation
Treatment strategies for atrial fibrillation (AF) are only moderately effective and do not prevent AF onset and progression. This difficulty of treatment predicts a great need to dissect root causes of AF and to develop novel therapies.
Emerging research findings indicate that heat shock proteins (HSP) mitigate AF onset and progression in experimental model systems for AF. In line with this, previous studies revealed that HSP-inducing compounds promote enhancement of contractile function and prevents loss of cellular integrity during AF.
Such an HSP inducing compound is L-glutamine, a semi-essential amino acid, already registered as a dietary supplement.
L-glutamine has cardioprotective effects
Clinical and experimental studies have consistently associated L-glutamine administration with increased HSP expression, especially HSP27 and HSP70 in organs. In the heart, L-glutamine may protect against atrial fibrillation-induced cell damage and as such may lower HSP excretion to the circulation.
Glutaminimize AF: the first AFIP study based on co-creation with patients
Therefore, AFIP in co-creation with patients with atrial fibrillation investigated the effect of L-glutamine supplementation on HSP27 and HSP70 serum levels and metabolite levels in patients with atrial fibrillation (n = 21).
After 3-months of L-glutamine supplementation, HSP27 and HSP70 levels significantly decreased. Also, patients with high HSP27 levels at baseline showed normalization of several metabolites related to the carbohydrates, nucleotides, amino acids, vitamins and cofactors metabolic pathways after 3-months L-glutamine supplementation.
In conclusion, L-glutamine supplementation reduces the serum levels of HSP27 and HSP70 within 3-months and normalizes metabolite levels. This knowledge may fuel future clinical studies on L-glutamine to improve cardioprotective effects that may attenuate AF episodes.
This study was sponsored by the non-profit organisation ‘Coolsingel’ and designed in co-creation with atrial fibrillation patients.
AFIP thanks all patients for their contribution.
The study has been published in the journal Cells.
Do you know someone who might be interested in this?
Related articles
Innovative Approaches to Treat Atrial Fibrillation: From Bench to Bedside
Guest Editors: Prof. Bianca Brundel AmsterdamUMC and founder of AFIP, and Dr. Xun Ai, Rush University Chicago Atrial fibrillation (AF), the most common progressive cardiac rhythm disorder, is present in
Atrial Tissue Conductivity Estimation For Analysis of Atrial Fibrillation
The Electrical Circuit of The Heart Have you ever considered your heart as an electrical circuit? That is how we, electrical engineers at TU Delft, look at the heart. To
Published Review Article by The AFIP Foundation: Diet-Based Solutions for AFib
On August 13th, 2024, a scientific review article, led by the AFIP Foundation in close collaboration with patient advocacy groups Plant-Powered Metro New York and Plant-Based Pittsburgh, was published in